-
Featured Authors
Archive
- July 2016 (1)
- June 2016 (2)
- April 2016 (1)
- October 2015 (2)
- September 2015 (3)
- August 2015 (2)
- July 2015 (4)
- June 2015 (12)
- May 2015 (4)
- April 2015 (1)
- March 2015 (2)
- November 2014 (1)
- October 2014 (2)
- September 2014 (2)
- June 2014 (1)
- May 2014 (2)
- March 2014 (1)
- February 2014 (2)
- October 2013 (1)
- September 2013 (1)
- August 2013 (1)
- July 2013 (1)
- June 2013 (2)
- April 2013 (1)
- February 2013 (2)
- January 2013 (1)
- October 2012 (1)
- September 2012 (3)
- August 2012 (1)
- January 2012 (3)
- December 2011 (2)
- October 2011 (3)
- August 2011 (3)
- July 2011 (2)
- June 2011 (12)
- April 2011 (2)
- January 2010 (1)
- November 2009 (1)
- October 2009 (47)
- September 2009 (37)
- August 2009 (1)
- June 2008 (3)
- May 2008 (2)
- April 2008 (1)
- February 2008 (6)
Category Archives: Business of Biotech
FOX Business: BIO CEO Jim Greenwood Discusses State of the Industry
BIO President and CEO Jim Greenwood recently appeared on Fox Business Risk & Reward with Deirdre Bolton to discuss the current state of the industry. Greenwood quickly debunked the “bubble” rumor by explaining the index continues to move up year over year and it is driven by strong science that results in strong returns and that increasing sophistication among investors allows them to more accurately assess company valuations than in the past. Further, Greenwood addressed Read More >
2015: A Promising Year for Biotech Jobs
If you’re in the biotech sector and are looking for a new career, you’re in luck: according to a recent survey by BioSpace, 70% of respondents believe new jobs will be on the horizon this year. The majority of respondents say that small firms will lead the hiring rush. The poll was split over where most hiring would occur, with 39% believing it would go to research and development jobs, and 39% believing it would Read More >
The Perfect Close
With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >
Choose Wisely My Friend- Survey Says, Identifying the Right R&D Partner is the Most Challenging Aspect of Outsourcing Market
A recent survey conducted by BIO confirms the increasing reliance on R&D outsourcing as biotech and pharmaceutical companies indicate speed, flexibility, and access to specialized resources drive pipeline strategies/decisions. Despite these biopharma companies having veteran teams with outsourcing experience, our survey results help quantify inefficiencies facing nearly every relevant organization. The survey polled a group of small biotech companies about their experience with CROs and other contract service providers. Over 80% of the companies surveyed were actively outsourcing portions of their pre-clinical or clinical pipelines. Nearly two-thirds of the companies surveyed dedicated more than 20% of their entire budget to these services in 2014. In addition, every company surveyed plans on maintaining Read More >
Don’t Go At It Alone- BIO BizLink and the Evolving R&D Marketplace
With companies in the biotechnology industry more frequently outsourcing R&D pipelines, selecting the right contract organization becomes more important. BIO, along with OnDeckBiotech, has recently launched a new online platform, BIO BizLink, that facilitates these relationships between biopharma companies and contract service providers. BIO BizLink serves as a peer-rated database for contract manufacturing organizations (CMOs) and contract research organizations (CROs) and their specific capabilities, while additionally providing secure project management tools to help companies work Read More >
